Literature DB >> 9012650

Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor.

U Olsson1, G Camejo, E Hurt-Camejo, K Elfsber, O Wiklund, G Bondjers.   

Abstract

The interaction of apoE lipoproteins with cells appears to be mediated by an association with basic sequences of proteoglycans and the apoB/E receptor. ApoB-100 has basic sequences, homologous with those of apoE, that form part of the apoB/E receptor-binding domain. These sequences of apoB-100 also interact with proteoglycans. We investigated whether such segments, in analogy with apoE, could act cooperatively on LDL interactions with proteoglycans and the receptor. As a model we used the two most basic regions of apoB-100, 3147 through 3157 and 3359 through 3367, connected by three glycines (3145-3157-GGG-3359-3367). Such segments may be proximal in LDL by the presence of a disulfide bridge between Cys(3167) and Cys(3297). The apoB heterodimer but not the separated monomers inhibited 125I-LDL degradation in fibroblasts and THP-1 cells by 50% at approximately 11 mumol/L. The heterodimer affinity with arterial proteoglycans was closer to that of LDL and higher than that of the individual peptides. The heterodimer appears to bind specifically to THP-1 cells, with a Kd of 6.2 x 10(-8) mol/L and a Bmax of 1.3 x 10(6) molecules/cell. Monoclonal antibody C-7, which recognizes the apoB receptor, inhibited the binding to cells. Treatment of fibroblasts with chondroitinase ABC or chlorate decreased 125I-LDL degradation markedly. Hydrolysis of pericellular proteoglycans of fibroblasts by chondroitinases reduced mostly the low-affinity, high-capacity component of LDL binding. This compartment appears to hold 70% of the cell-associated LDL when internalization is inhibited at 4 degrees C. Therefore, cell-surface chondroitin sulfate/dermatan sulfate proteoglycans appear to modulate binding and receptor-mediated internalization of LDL. This may be caused, at least in part, by the association of proteoglycans with the apoB-100 segments 3145 through 3157 and 3359 through 3367.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012650     DOI: 10.1161/01.atv.17.1.149

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

3.  Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.

Authors:  J Borén; K Olin; I Lee; A Chait; T N Wight; T L Innerarity
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

4.  Glycosaminoglycan-lipoprotein interaction.

Authors:  U Olsson; G Ostergren-Lundén; J Moses
Journal:  Glycoconj J       Date:  2001-10       Impact factor: 2.916

5.  Identification of a domain in apolipoprotein B-100 that inhibits the procoagulant activity of tissue factor.

Authors:  C Ettelaie; N J James; J M Adam; K P Nicola; B R Wilbourn; K R Bruckdorfer
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

6.  Antigen- and Epitope-Delivering Nanoparticles Targeting Liver Induce Comparable Immunotolerance in Allergic Airway Disease and Anaphylaxis as Nanoparticle-Delivering Pharmaceuticals.

Authors:  Qi Liu; Xiang Wang; Xiangsheng Liu; Yu-Pei Liao; Chong Hyun Chang; Kuo-Ching Mei; Jinhong Jiang; Shannon Tseng; Grant Gochman; Marissa Huang; Zoe Thatcher; Jiulong Li; Sean D Allen; Luke Lucido; Tian Xia; Andre E Nel
Journal:  ACS Nano       Date:  2020-12-22       Impact factor: 15.881

7.  Therapeutic approaches using host defence peptides to tackle herpes virus infections.

Authors:  Håvard Jenssen
Journal:  Viruses       Date:  2009-11-18       Impact factor: 5.048

8.  Immunization using ApoB-100 peptide-linked nanoparticles reduces atherosclerosis.

Authors:  Kuang-Yuh Chyu; Xiaoning Zhao; Jianchang Zhou; Paul C Dimayuga; Nicole Wm Lio; Bojan Cercek; Noah T Trac; Eun Ji Chung; Prediman K Shah
Journal:  JCI Insight       Date:  2022-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.